The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma.

Cancers (Basel) · 2021 · PMC8074001 · PMID 33923396

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

a strong trendp = 0.051so close (0.05 < p ≤ 0.1)

While results for 2-year progression-free survival show a strong trend toward favoring rituximab treatment, they were not statistically significant, but only by a slight margin (HR 0.52, 95% CI 0.32–0.86, p = 0.051).

also in 5,725 other papers

of borderline significanceno p-value reported

showed a trendno p-value reported

The IELSG32-trial showed no beneficial effect on CR rates, progression-free and overall survival by solely adding rituximab to a high-dose methotrexate-based chemotherapy regimen, although the difference in progression-free survival showed a trend of borderline significance.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.